Intellia Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
106.60
|
|
Average Rating
|
4.29
|
|
# Strong Buys
|
14
|
|
# Buys
|
10
|
|
# Holds
|
3
|
|
# Sells
|
0
|
|
# Strong Sells
|
1
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-1.28
|
-1.49
|
-0.21
|
-16.41%
|
|
2022-06-30
|
-1.31
|
-1.33
|
-0.02
|
-1.53%
|
|
2022-03-31
|
-1.10
|
-1.96
|
-0.86
|
-78.18%
|
|
2021-12-31
|
-0.94
|
-1.09
|
-0.15
|
-15.96%
|
|
2021-09-30
|
-0.84
|
-0.97
|
-0.13
|
-15.48%
|
|
2021-06-30
|
-0.63
|
-1.01
|
-0.38
|
-60.32%
|
|
2021-03-31
|
-0.66
|
-0.69
|
-0.03
|
-4.55%
|
|
2020-12-31
|
-0.60
|
-0.69
|
-0.09
|
-15.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-4.78
|
|
2021-12-31
|
-3.76
|
|
2020-12-31
|
-2.40
|
|
2019-12-31
|
-2.11
|
|
2018-12-31
|
-1.99
|
|
2017-12-31
|
-1.86
|
|
2016-12-31
|
-10.78
|